Press Releases

 

Company News

  Date Title and Summary View
Feb 15, 2017
LAWRENCEVILLE, N.J., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced the pricing of a public offering with expected total gross proceeds of approximately $5.0 million. The offering was priced at $0.23 per share of common stock (or common stock equivalent), with each share of common stock (o...
Jan 19, 2017
LAWRENCEVILLE, N.J., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that it will present two posters at the American Society of Clinical Oncology (ASCO) - Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium being held from February 23 - 25, 2017 in Orlando, FL.  The symposium will foc...
Jan 18, 2017
LAWRENCEVILLE, N.J., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical stage oncology drug development company, today announced that the United States Patent and Trademark Office has granted U.S Utility Patent No. 9,492,385 B2 - Temperature-Sensitive Liposomal Formulation, which is directly applicable to the method o...
Jan 17, 2017
Fourth Cohort of Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1, A Novel IL-12 DNA-based Immunotherapy, in Combination with the Standard of Care LAWRENCEVILLE, N.J., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced data from the fourth cohort of patients in its Phase Ib ...
Dec 20, 2016
LAWRENCEVILLE, N.J., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has entered into a definitive agreement with several institutional investors to purchase an aggregate of approximately $1.8 million of shares of common stock in a registered direct offering. The Company agreed to...
Dec 16, 2016
CFDA Indicates that Positive Phase III OPTIMA Data Could Support Direct Regulatory Filing in China Expect to Initiate Additional Sites for Phase III OPTIMA Trial in Vietnam in Early 2017 LAWRENCEVILLE, N.J., Dec. 16, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today provided an update on its Phase III OPTIMA program for Therm...
Dec 1, 2016
LAWRENCEVILLE, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that the independent Data Safety Monitoring Board (DSMB) has completed its safety review of data from the first four patient cohorts in the ongoing Phase 1b OVATION Study.  Based on the DSMB's recommendation, the study will continue as planned...
Nov 30, 2016
LAWRENCEVILLE, N.J., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN) today announced that following a review of data from its multinational, randomized pivotal Phase III clinical study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) for primary liver cancer (the OPTIMA Study), the study's Data Mo...
Nov 29, 2016
NIH Analysis of Data from Celsion's HEAT Study Reaffirms Correlation Between Increased RFA Burn Time per Tumor Volume and Significant Improvements in Overall Survival Prior Subgroup Analysis of HEAT Study by Celsion Demonstrated a Two-Year Overall Survival Benefit for Patients Treated with ThermoDox® Plus Optimized RFA Compared with Optimiz...
Nov 10, 2016
Third Cohort of Patients Continues to Show Clinically Meaningful Responses in the Evaluation of GEN-1, A Novel IL-12 DNA-based Immunotherapy, in Combination with the Standard of Care Top Line Translational Data from First Two Cohorts Demonstrates Potential Immune Activation LAWRENCEVILLE, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Celsion Corp...
Page: FirstPrevious
3
... NextLast
= add release to Briefcase
Share This